Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02593916 · ClinicalTrials.gov registry record
Response to Medication Registry
A clinical trial of Adverse Drug Events, sponsored by Intermountain Health Care.
- Completed
- Registry status
- 196
- Enrollment target
- 1
- Study location
NCT02593916: Completed study of Adverse Drug Events, sponsored by Intermountain Health Care.
NCT02593916 is a study of Adverse Drug Events that has completed, run by Intermountain Health Care. The registered enrollment target is 196 participants, below the 757-participant average among 6 other Adverse Drug Events trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02593916, a study of Adverse Drug Events, has completed, sponsored by Intermountain Health Care.
- COMPLETED
- Registry status
- 196 participants
- Enrollment target
- 1
- Study location
Study Summary
To create a registry/database of patients who either have taken drugs that treat cardiovascular conditions or that have presented with cardiovascular symptoms that may be related to medication.
Primary Outcome
We will monitor clinical responses to medications for 5 years and look for genetic markers and biomarkers that correlate with these responses.
Conditions Studied
Study Locations (1)
Utah
- LDS Hospital - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2007-03 |
| Est. Completion | 2018-12 |
What the finished NCT02593916 record still lists
NCT02593916 is an observational study that tracks outcomes without assigning an intervention. The registered 196 participants enrollment target is mid-sized for trials with a published cap, below the 757-participant average among 6 other Adverse Drug Events trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Adverse Drug Events appearing as the primary indexed condition, and to 0 interventions.
NCT02593916 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT02593916 about?
NCT02593916 is a clinical study titled "Response to Medication Registry". To create a registry/database of patients who either have taken drugs that treat cardiovascular conditions or that have presented with cardiovascular symptoms that may be related to medication.
What is the current status of trial NCT02593916?
This trial is currently completed. The enrollment target is 196 participants. The study started on 2007-03. Estimated completion is 2018-12.
What conditions does trial NCT02593916 study?
This clinical trial studies the following conditions: Adverse Drug Events.
Who is sponsoring clinical trial NCT02593916?
This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02593916 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adverse Drug Events
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Geriatric Emergency Department Pharmacologic Harm Prevention Project
RECRUITING · NA
-
Multi-Center Medication Reconciliation Quality Improvement Study
COMPLETED · NA
-
Improving Safety by Basic Computerizing Outpatient Prescribing
COMPLETED · Phase 2
-
Patient Profiling and Provider Feedback to Reduce Adverse Drug Events
COMPLETED · NA
-
The Secure Messaging for Medication Reconciliation Tool (SMMRT) Trial
COMPLETED · NA
-
Enhancing the Detection and Management of Adverse Drug Events in Nursing Homes
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02822768 · 196 participants · NA
Packing Versus no Packing for Cutaneous Abscess
- NCT04250259 · 196 participants · Phase 2
SAMe Trial for Patients With Alcoholic Cirrhosis
- NCT05142592 · 196 participants · Phase 1
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
- NCT05317832 · 196 participants · Phase 2
Using Smartphones to Improve Physical Activity Levels of Individuals With Spinal Cord Injury
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia